But patients would rather treat their sleep apnea with tirzepatide (Zepbound), a GLP-1 weight-loss drug, researchers found. "The results highlight a need for real-world comparative effectiveness ...

Key TakeawaysPatients and doctors are disagreeing about sleep apnea treatmentDoctors favor the use of CPAP machinesBut patients with obesity would rather use Zepbound to ease their apneaMONDAY, June 9 ...

But Zepbound is only for people with obesity and sleep apnea, the AASM noted. Also, Zepbound can reduce the severity of sleep apnea through weight loss but might not cure the problem.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Key Takeaways Patients and doctors are disagreeing about sleep apnea treatment Doctors favor the use of CPAP machines But patients with obesity would rather use Zepbound to ease their apnea MONDAY ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Zepbound is the only one that's FDA-approved for sleep apnea, specifically among people with obesity (defined as a BMI of over 30). But both semaglutide and tirzepatide may help with sleep apnea ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...